This cell line overexpresses the ER-resident ceramide synthase Trh4 (transduced by CRISPR) and lacks the H2-Kb gene.
| Inventor | Institute |
|---|---|
| Thorbald Van Hall | Leiden University and Leiden University Medical Center; Stichting Oncode Institute |
| SKU: | 157678 |
|---|---|
| Product description: | This cell line overexpresses the ER-resident ceramide synthase Trh4 (transduced by CRISPR) and lacks the H2-Kb gene. It serves as a control in helping to understanding T-cell recognition of the Trh4-derived peptide presented by the MHC class I molecule H2-Db. This peptide-epitope is a prototypic example of a neo-antigen selectively presented by cells with processing defects in the classical MHC class I (MHC-I) pathway. RMA cells have an intact processing pathway and a functional TAP peptide transporter, but overexpress the Trh4 protein and therefore can present the Trh4 peptide. Clear T cell recognition can be observed since the irrelevant MHC class I H2-Kb was knocked out.This population acts as a clear control. CRISPR edited RMA cells. |
| Production details: | Retroviral transduction of the mouse Trh4 gene in an IRES-GFP construct and CRISPR/Cas9 technology |
| Additional notes: | CRISPR edited RMA cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide… |
| Cellosaurus ID: | CVCL_C0DQ |
| Parental cell line: | RMA |
| Disease: | Cancer |
| Cat. #: | 157678 |
|---|---|
| Tool sub type: | Primary |
| Unit size: | 1×10^6 cells / vial |
| Cancer types: | Blood cancer |
| Research Fields: | Cancer |
| Organism: | Mouse |
| Tissue: | Lymphatic Tissue |
| Model: | Knock-Out |
| Cancer Types In Detail: | Mouse Leukemia |
| Format: | Frozen |
|---|---|
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry ice |
| Growth medium: | Suspension cells in DMEM+8% FCS |
| Recommended controls: | RMA.Trh4 Db KO cells |
| Mycoplasma free: | Yes |
| Biosafety level: | 1 |
| References: |
Doorduijn et al. 2018. Oncoimmunology. 7(3):e1382793. PMID: 29399388. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.